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Abstract 
Atopic dermatitis (AD) is one of the most common skin diseases. Various features 
present in AD like inflammation, reduced apoptosis, altered epidermal differentiation 
and hyperproliferation as well as permeability dysfunction are also regulated by 
retinoids.  
The aim of our study is to identify the retinoid signaling pathways and retinoid 
concentration profiles in AD skin. 
Human skin biopsies were obtained from healthy volunteers (HS) (n=6) and AD 
patients (n=6), with both affected (AS) and non-affected (NAS) skin. The gene 
expression of retinoid receptors, retinoid-binding proteins and retinoid-metabolizing 
enzymes was investigated by QRT-PCR. Retinoid concentrations in serum and skin 
were measured via high performance liquid chromatography mass spectrometry – 
mass spectrometry. 
Our results show that the target gene expression of retinoid receptor regulated 
pathways is significantly decreased in AS and NAS of AD patients. CYP26A1, 
transglutaminase 2 and retinoic acid receptor responder 1 decreased in NAS and AS 
in comparison to HS. The main retinoic acid synthesizing enzyme, retinal-
dehydrogenase 1, was significantly lower expressed in NAS (0,1%) and AS (1%) in 
AD patients. Analysis of retinoid concentration in serum and skin showed comparable 
all-trans retinoic acid (ATRA) and retinol (ROL) concentrations from AD and healthy 
serum, but strongly reduced ATRA and ROL concentrations in affected and non-
affected skin in comparison to healthy skin.  
Our data indicate that retinoid transport, synthesis, concentrations and signaling are 
strongly decreased in the affected but also in non-affected skin of atopic dermatitis 
patients suggesting a general intrinsic influence on skin retinoid signaling pathway in 
AD patients.  
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Introduction 
 
Vitamin A and its derivatives, the retinoids, are important for skin physiology (1). 
Retinoids regulate various effects in differentiation, proliferation, apoptosis, immune 
regulation, barrier properties (2-3) and sensorial functions (4) in numerous skin cell 
types. Several skin diseases like psoriasis (5), ichthyosis (6), skin cancers (7), acne 
(8) and various other dermatoses are related to alterations in retinoid metabolism / 
signaling. Retinoid-based treatments have been shown to be beneficial for various 
therapeutic approaches of these skin diseases (9). Topical as well as systemic 
treatments with retinoids like, retinoic acid and synthetic retinoic acid analogues or 
derivatives which modify retinoid metabolism are used already in therapy (1, 10-12).  
  
Retinoids mainly mediate their activity via nuclear hormone receptors, the retinoic 
acid receptors (RAR) with all-trans retinoic acid (ATRA) as the major ligand and the 
retinoid-X receptors (RXR) with 9-cis retinoic acid (9CRA) as a potential candidate 
ligand (13-15). The synthesis, degradation, cellular binding and receptor mediated 
binding of all-trans retinoic acid is tightly regulated (16). 
 
Studies reported that vitamin A / retinoids modify the outcome and severity of atopic 
diseases, mainly the immune phenotype of these diseases (17-18). Skin specific KO-
model of the nuclear retinoid receptors RAR and RXR and combinatory KO-mice 
models in skin display that retinoid signaling is highly important for the skin 
phenotype of AD (19-20). In this study we investigated genes known to be involved 
in retinoid regulation, metabolism, receptors and signaling of endogenous retinoids 
(Fig. 1) as well as retinoid target genes regarding their expression profile in skin from 
healthy volunteers as well as non-affected and affected skin from atopic dermatitis 
patients.  
 
The aim of the study was to identify the expression profile from genes involved in 
retinoid metabolism, regulation and signaling as well as retinoid receptors and 
retinoid target genes in the skin. This was achieved by a comparable analysis of 
healthy and diseased skin biopsies and the additional consideration of serum as well 
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as skin retinoid concentrations via sensitive high performance liquid chromatography 
mass spectrometry – mass spectrometry (HPLC MS-MS) methodology. 
  
5 
Materials and methods 
 
Skin biopsies and serum samples 
Skin punch biopsy specimens were taken after obtaining informed consent in 
involved areas from 6 patients with atopic dermatitis (2 male and 4 female patients; 
average age, 31 years), according to the declaration of Helsinki, and from 6 non-
atopic healthy volunteers (2 male and 4 female individuals; average age 30 years, 
see table 1) characterized by the absence of personal or family history of atopic 
disease. In case of AD patients, one biopsy of affected skin and one biopsy of non-
affected skin were taken from each patient. Epidermis represents ca. 20-30 % of the 
skin biopsy used for analysis. Specimens were immediately frozen in dry ice and 
stored at -70 °C until RNA isolation or HPLC analysis was performed. At the same 
time, serum samples were drawn from the same patients and were kept at -70°C 
until analysis. Ethical approval for the study was obtained from the local ethics 
committee (EA1/168/06) and from each volunteer a signed informed consent was 
obtained. 
 
Analysis of mRNA expression  
Skin samples were homogenized in Tri® reagent solution and total RNA was isolated 
according to the manufacturer’s guidelines. The concentration and purity of RNA 
were measured by means of NanoDrop spectrophotometer (Thermo) and its quality 
was checked using agarose-gel-electrophoresis. For real-time quantitative PCR (QRT-
PCR), total RNA was reverse transcribed into cDNA using the Super Script II First-
Standard Synthesis System (Invitrogen). QRT-PCR was carried out in triplicate using 
pre-designed MGB assays ordered from Applied Biosystems, on an ABI Prism 7900. 
Relative mRNA levels were calculated using either the comparative CT or standard 
curve methods normalized to cyclophilin A mRNA. Sequence Detector Software 
(version 2.1) was utilized for data analysis and relative fold induction was determined 
by the comparative threshold cycle method.  
 
High performance liquid chromatography mass spectrometry – mass 
spectrometry (HPLC MS-MS) analysis: 
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Concentrations of retinol and retinoic acids (Ras) were determined in human serum 
and skin biopsies by our HPLC-MS-MS method (21). In summary, 100 mg of the skin 
biopsy (if samples were under 100 mg water was added up to the used standard 
weight: 100 mg) or 100 μl serum was diluted with a threefold volume of isopropanol, 
the tissues were minced by scissors, vortexed for 10 seconds, put in a ultra sonic 
bath for 5 minutes, shaken for 6 minutes and centrifuged at 13000 rpm in a Heraeus 
BIOFUGE Fresco at +4°C. After centrifugation, the supernatants were dried in an 
Eppendorf concentrator 5301 (Eppendorf, Germany) at 30°C. The dried extracts 
were resuspended with 60 μl of methanol, vortexed, shaked, diluted with 40 μl of 60 
mM aqueous ammonium acetate solution and transferred into the autosampler and 
subsequently analysed. 
 
Statistics 
Data are shown as mean and standard error mean values of three measurements per 
data point. Statistical analysis was performed using the program SPSS 16.0. A p 
value of less than 0.05 was considered significant. 
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Results 
 
A. Expression profiles of retinoid signalling pathways in AD skin samples 
 
Firstly we investigated the expression profile of genes, which are involved in retinoid-
homeostasis, -regulation, - metabolism, retinoid receptors and retinoid-target genes. 
These data show that there is a severe dysregulation of retinoid-homeostasis, -
metabolism and -signalling present in affected and non-affected AD skin. 
 
Dysregulation of retinol homeostasis / retinyl ester synthesis regulation 
Retinol binding protein (RBP) 4 is the carrier protein involved in the transport of 
retinol and its mRNA expression was non-significantly down-regulated in atopic 
dermatitis affected skin (Fig. 2d). The mRNA expression of diacylglycerol 
acyltransferase (DGAT) showed a slight decrease in both affected and non-affected 
skin compared to healthy skin, while lecithin retinol acyltransferase (LRAT) was 
significantly up-regulated in non-affected skin of atopic dermatitis (Fig. 2a).  
 
Dysregulation of retinal synthesis 
Expression levels of beta - carotene 15,15`- monooxygenase (BCMO1) and beta-
carotene-dioxygenase-2 (BCMO2) mRNA were not significantly altered in skin with 
atopic dermatitis compared to healthy skin (Fig. 2a). Retinol dehydrogenases and 
alcohol dehydrogenases are enzymes which are responsible for converting retinol to 
retinal. Retinol dehydrogenase (RDH) 2, RDH10 and RDH16 showed a very similar 
pattern in their mRNA expression. RDH2 was statistically significantly induced in both 
affected and non-affected atopic dermatitis skin, compared to healthy skin. 
Augmented mRNA expression of RDH10 and RDH16 was observed in atopic 
dermatitis affected skin, vs. healthy skin. The mRNA expression of alcohol 
dehydrogenase (ADH) 1C was significantly reduced in non-affected and affected AD 
skin (Fig. 2b). 
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CRBP 1 is the intracellular carrier of retinol and its mRNA expression showed a 
significant down-regulation in case of skin with atopic dermatitis, both in non-
affected and affected AD skin (Fig. 2d).  
 
Reduced retinoic acid synthesis in affected and non-affected skin of atopic 
dermatitis 
Retinal dehydrogenase (RALDH) or acetaldehyde dehydrogenase converts 
retinaldehyde to RA. We observed a significant decrease of RALDH1 mRNA levels in 
skin with atopic disease, both in affected and non-affected skin, while the mRNA 
expression of RALDH2 and RALDH3 did not show significant alterations in our 
experimental setup (Fig. 2c). 
 
CRABP2 is an intracellular retinoic acid transporter protein and its mRNA expression 
was not altered in skin of atopic dermatitis patients. Also CRABP1 did not show a 
significant alteration in diseased skin, in comparison to healthy skin (Fig. 2d). 
 
Reduced expression of RA degradation / metabolism enzymes in affected 
as well as non-affected skin of atopic dermatitis 
mRNA expression level of RA-degrading enzymes was determined and revealed a 
significant decrease in case of CYP26A1 and CYP2S1, both in affected and non-
affected AD skin. However mRNA expression of CYP26B1 could not be detected in 
our experimental setup (Fig. 2e). 
 
Increased expression of RXRα in non-affected skin of atopic dermatitis 
RARα mRNA levels did not show any significant alteration in diseased compared to 
healthy skin, while mRNA expression of RARβ was slightly but non-significantly up-
regulated in non-affected AD skin. By contrast, the expression of RARγ was 
comparable between atopic dermatitis and healthy skin. The expression of RXRα was 
significantly increased in non-affected AD skin and affected AD skin (Fig. 2f). 
 
Expression of retinoid target genes in atopic dermatitis 
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The mRNA expression of retinoic acid receptor responder (RARRES1) was 
significantly decreased in case of atopic dermatitis in non-affected and affected skin, 
in comparison to healthy skin. Also TGM2 showed a significant decrease both in non-
affected and in affected skin of atopic dermatitis. By contrast, HB-EGF mRNA 
expression was comparable between AD patients and healthy volunteers (Fig. 2g). 
 
Due to strongly reduced retinoid signalling pathways in AD skin we next analysed 
ATRA and ROL concentrations in skin biopsies and serum of healthy volunteers and 
diseased patients: 
 
B. Reduced concentrations of retinol and all-trans retinoic acid in AD skin, 
but not in serum of AD patients 
 
Skin concentrations of ATRA and ROL were strongly reduced in affected (ATRA 0.4 / 
0.5 ng/g; ROL 37 / 46 ng/g) but also in non-affected skin biopsies (ATRA 0.3 / 0.6 
ng/g; ROL 32 / 54 ng/g) from an AD patient in comparison to ATRA and ROL 
concentrations in healthy skin (ATRA 0.7 / 1.2 ng/g; ROL 207 / 253 ng/g) (Fig. 3).  
 
Serum concentrations of ATRA 2,8 ± 0,8 ng/ml and ROL 510 ± 217 ng/ml were 
comparable in healthy volunteers and AD patients ATRA 2,9 ± 1,0 ng/ml and ROL 
573 ± 191 ng/ml (Table 2). 
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Discussion 
 
In this study we demonstrated that in affected and in non-affected human tissue 
biopsies the retinoid transport, synthesis, concentrations, signaling and homeostasis 
are severely dysregulated in comparison to skin from healthy volunteers. To our 
surprise even the skin of non-affected areas of atopic dermatitis patients displayed 
dysfunction of retinoid signaling, suggesting an intrinsic disease specific dysfunction 
for the regulation of retinoid binding proteins, metabolizing enzymes, retinoid 
response target genes expression as well as retinoid concentrations. Interestingly the 
mRNA expression of the majority of retinoid response target genes like CRBP1, 
CYP26A1, CYP2S1, TGM2 and RARRES1 were significantly down-regulated, which is 
in accordance with the decreased level of retinoic acid determined in AD skin.  
 
ATRA is the major RAR ligand and its concentration in the mammalian skin is tightly 
regulated in a specific spatiotemporal manner (19, 22-23). Various cell types in the 
skin and especially in the inflamed skin have been shown to be able to synthesize the 
bioactive retinoic acid (24). We found that retinoid response target genes like 
RARRES1, CRBP1, CYP26A1, CYP2S1 and TGM2 are significantly decreased in 
affected as well as non-affected human skin of AD patients, while the expression of 
other retinoid targets genes like RARβ, CRABP2 and HB-EGF were not altered. HPLC 
MS-MS data additionally confirmed that the concentration of ATRA is much lower in 
affected and in non-affected AD skin in comparison to skin from healthy volunteers; 
no difference was detected between affected and non-affected AD skin (Fig. 3). This 
might also be a cause or result of lower delivery of the retinoic acid precursor, retinol 
(ROL) via RBP4 to the skin, while both ROL levels as well as RBP4 expression are 
lower in affected AD skin samples in comparison to healthy volunteers (Fig. 2 and 3).  
 
The additional analysis of serum concentrations from the same patients and 
volunteers displayed comparable ATRA levels between AD patients and healthy 
volunteers (Table 2). These data suggest a systemic non-RA based origin for this 
skin specific dysfunction of retinoid mediated signaling in AD. We suggest and partly 
know already that besides ATRA (the main signaling molecule for retinoid target 
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gene expression), which is much lower in skin of atopic patients, also other relevant 
and still non-identified bioactive retinoids or / and other retinoid mediated response 
pathways involving other retinoid-activated nuclear receptors must be present. 
Alternative activators of RAR and RXR may be responsible for stable and non-altered 
expression of the retinoid target genes RARβ, CRABP2 and HB-EGF in atopic skin 
even when ATRA levels are present in much lower concentrations. Identification of 
novel endogenous RAR as well as RXR ligands is under investigation in our 
laboratories. 
 
The expression of the major retinoic acid synthesizing enzyme in the skin the 
RALDH1 is significantly decreased in AD skin vs. healthy skin (25). This strong down-
regulation in affected and non-affected AD skin is suggested to be mainly responsible 
for lower ATRA concentrations and thereby for the significantly lower retinoid 
mediated signaling in the skin of AD patients.  
 
Deficiency of retinoids / retinoid signaling in the skin or general vitamin A deficiency 
has been associated to various symptoms also seen in the atopic dermatitis skin 
phenotype. TH1 / TH2 shift (26), altered apoptosis (27), altered skin differentiation 
and proliferation (28) and increased bacterial skin colonization (29) were associated 
with vitamin A deficiency or deletion of retinoid receptor mediated signaling in 
transgenic skin specific mouse models (19-20). Whether lower retinoid signaling and 
lower retinoic acid concentration in AD skin is based on an intrinsic abnormality is 
under examination in various in vivo studies in our laboratories.  
 
 
Remarkable is the reduced gene expression of the retinoid-target genes CRBP1, 
CYP26A1, CYP2S1, TGM2, RALDH1, RARRES1 and the ADH1C in non-affected AD 
skin comparably to affected AD skin. We suggest that a general and intrinsic 
abnormality is responsible for this dysregulation and maybe a result of systemic 
chronic inflammation. A different expression profile was observed for LRAT and RXRα 
which are exclusively increased in non-affected AD skin (Fig. 2) confirming also a 
general intrinsic abnormality responsible for this dysregulation of retinoid-signaling 
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(LRAT, RXRα) and maybe of other RXRα-heterodimer mediated pathways in non-
affected AD skin. This increased expression of LRAT and RXRα maybe a response of 
the non-affected skin on intrinsic chronic inflammation to further enable and balance 
reduced retinoid signaling. Additionally the increased expression of RDH2 and RDH10 
may be a skin based response to enable and balance retinoid signaling in the skin. 
 
An altered nutrition with high vitamin A as well as pro-vitamin A carotenoids resulting 
in significantly higher serum levels of all-trans retinoic acid (30) or increased 
ingestion of dietary fats which lead to increased expression of various factors / 
enzymes important for retinoid signaling (31) might contribute also to this altered 
retinoid signaling in affected as well as non-affected skin of AD patients.  
 
Several approaches using nutritional supplementations with carotenoids and various 
retinoids as well as systemic inflammation / allergic sensitization are in progress to 
elucidate why both in affected as well as in non-affected skin of atopic dermatitis 
patients retinoid transport, synthesis, concentrations and signaling are strongly 
decreased. We suggest that the answer to this question may help to understand the 
pathogenesis of atopic dermatitis and may lead to strategies for atopy prevention. 
Based on our observations we suggest that topical retinoid applications using single 
or combinations of selective retinoids would be highly beneficial for atopic dermatitis 
therapy. 
 
In summary, more studies are needed to identify how retinoid transport, metabolism, 
concentrations and signaling are regulated in the skin and the regulation of key 
players like RALDH1, which is the major enzyme important for retinoic acid synthesis 
in human skin, in AD patients in comparison to healthy volunteers. Animal studies 
using topical as well as systemic application of various retinoids and KO animal 
models of retinoid synthesizing enzymes and retinoid receptors are in progress. We 
conclude that the retinoid signaling pathway is dysregulated in AD patients based on 
an abnormal retinoid transport, synthesis and concentrations which might contribute 
to the pathogenesis of AD, but also offer novel therapeutic approaches. 
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Table: 
 
Table 1: Clinical and basic demographic data from the healthy and diseased donors 
 
    Healthy volunteers  AD patients 
age in years  30 ± 11    31 ± 14 
gender   67 % female    67 % female 
SCORRAD   0 ± 0     36 ± 11 
total IgE (KU/L)  32 ± 17    1879 ± 764 
 
 
 
 
Table 2: Concentrations of ATRA and ROL in ng/ml in serum of healthy volunteers 
(HEALTHY, n=6) and atopic dermatitis volunteers (AD, n=6). There were no 
significant differences between healthy volunteers and AD patients. For converting 
concentration into molar, 3 ng/ml ATRA and 2,86 ng/ml ROL represent a 
concentration of 10 nM. 
 
   ATRA   ROL 
HEALTHY  2,8 ± 0,8   510 ± 217  
AD   2,9 ± 1,0   573 ± 191  
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 Figure 1: 
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Figure 2: 
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Figure 3: 
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Figure legends: 
 
Figure 1:  
General scheme about retinoid signaling pathway including structures and involved 
binding proteins and retinoid-metabolizing enzymes: RA- retinoic acid, RDH – retinol 
dehydrogenase, RALDH – retinaldehyde dehydrogenase, BCMO - beta carotene 
oxygenase, CRBP - cellular retinol binding-protein, CRABP – cellular retinoic acid 
binding-protein, LRAT – lecithin retinol acyltransferase, DGAT – diacylglycerol 
acyltransferase, RBP4 – retinol binding protein. 
 
Figure 2: 
Expression profiles of genes involved in retinoid transport, metabolism and signaling 
pathway in healthy volunteers as well as in the skin of affected and non-affected AD-
skin. HS – healthy skin, NAS – non-affected skin, atopic dermatitis, AS – affected 
skin, atopic dermatitis, * - p< 0.05, ** - p < 0.01, *** - p < 0.001 
 
Figure 3: 
HPLC MS-MS chromatogram of all-trans retinoic acid (ATRA) and retinol (ROL) using 
specific MS-MS tracks for ATRA and ROL from representative human skin biopsies of 
one affected and one non-affected skin biopsy from one AD-patient and one healthy 
volunteer. The two values represent the concentrations from the two independent 
determinations using the skin of two different healthy as well as AD-patients. Y-Axis 
of HPLC MS-MS chromatograms of the measured skin samples are the same 
magnitude for better visualization and comparison. 
 
